WO1996028008A2 - Novel cosmetic or dermatological compositions for controlling skin ageing - Google Patents
Novel cosmetic or dermatological compositions for controlling skin ageing Download PDFInfo
- Publication number
- WO1996028008A2 WO1996028008A2 PCT/FR1996/000811 FR9600811W WO9628008A2 WO 1996028008 A2 WO1996028008 A2 WO 1996028008A2 FR 9600811 W FR9600811 W FR 9600811W WO 9628008 A2 WO9628008 A2 WO 9628008A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- approximately
- weight
- composition
- composition according
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9741—Pteridophyta [ferns]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
Definitions
- the invention relates to a new cosmetic or dermatological composition intended to combat aging of the skin and / or to increase the elasticity of the skin.
- the aging of the skin is a complex phenomenon, involving many more or less slow reactions and which lead to a decrease in skin elasticity and the appearance of wrinkles.
- This product is yellowish brown and fluorescent.
- fructolysine is itself degraded into N- (carboxymethyl) lysine or is transformed, after reaction with an arginine residue, to finally give pentosidine.
- elastases Two types can be found in the skin. First of all, the leukocyte elastase is released by polymorphonuclear cells following the exposure of the skin to tension or stress, in particular ultraviolet radiation, pollution, infection, etc. (ref. 8). On the other hand, elastases belonging to the class of metalloproteases are synthesized by fibroblasts of the dermis and this in an increasing manner with age (ref. 9).
- the main aim of the present invention is therefore to provide a new cosmetic or dermatological composition with improved anti-glycation and anti-elastase combined action and making it possible to avoid the formation of free radicals.
- Another object of the present invention relates to the use of anti-glycation compounds and anti-elastase compounds for the preparation of a cosmetic composition.
- composition according to the present invention with a view to combating aging and / or increasing the elasticity of the skin, is characterized in that it comprises a first active principle chosen from natural or synthetic compounds capable of inhibiting the formation of Amadori products by reaction non-enzymatic of sugars, in particular glucose, with the collagen of the skin, said first active principle consisting of a single compound or of a mixture of several compounds; and in that it comprises a second active principle chosen from natural or synthetic compounds capable of inhibiting the activity of skin elastases, said second active principle consisting of a single compound or of a mixture of several compounds .
- the present invention results from the surprising discovery that certain products can block the glycation of proteins at a stage prior to that of the formation of Amadori products.
- the first active principle is chosen in particular from amino acids, preferably basic, in particular lysine, arginine, histidine; peptides, preferably those containing one or more basic amino acids; allantoin; vitamin E; vitamin B 1 ; vitamin B 6 ; thiourea; dithiothreitol; organic silicon derivatives and / or derivatives of these products.
- the amino acid derivatives include in particular lysine pyrrolidone carboxylate, arginine pyrrolidone carboxylate, arginine aspartate.
- the second active principle is chosen from compounds capable of blocking the action of leukocyte elastase and / or elastases synthesized by fibroblasts. It is chosen in particular from plant extracts rich in tannins, in anthocyanosides, procyanidolic oligomers, soy extract, in particular soy protein extracts, ⁇ -1-anti-trypsin, algae extracts, especially hydrolysates of green algae proteins and micro algae extracts, polysaccharides, in particular sulfated polysaccharides, ceramides.
- the composition comprises, as a percentage by weight relative to the total weight of the composition, from approximately 0.01% to approximately 50% by weight of said first active principle, preferably from approximately 0.1% to about 10% by weight, more preferably from about 0.2% to about 5% by weight and from about 0.01% to about 50% by weight of said second active ingredient, preferably from about 0.1% to about 10% by weight, more preferably from about 0.5% to about 5% by weight.
- the composition further comprises at least one natural or synthetic compound activating the synthesis of collagen, in particular an extract of Centella asiatica, ascorbic acid, peptides, ⁇ -glucans or seaweed or oat extracts containing them, or derivatives of these products.
- the concentration of compound activating the synthesis of collagen varies from approximately 0.01% to approximately 10% by weight, preferably from approximately 0.05% to approximately 5% by weight relative to the total weight of the composition. .
- the composition further comprises at least one natural or synthetic compound capable of preventing the production of free radicals, thus improving the inhibitory properties of the formation of free radicals of the first active principle.
- vitamin E or its esters vitamin C
- plant extracts rich in flavonoids or polyphenols such as Ginkgo biloba, green tea, thistle, etc.
- caffeic acid ferulic acid
- glutathione enzymes such as superoxide dismutase, glutathione reductase and glutathione peroxidase, zinc salts, mannitol or a derivative of these products.
- the concentration of compound inhibiting the production of free radicals varies from approximately 0.01% to approximately 20% by weight, preferably from about 0.1% to about 5% by weight relative to the total weight of the composition.
- the composition further comprises at least one natural or synthetic hydrating compound, in particular polyols, a constituent of the natural hydration factor
- NMF Natural Moisturing Factor
- urea an amino acid
- honey extract a honey extract
- hyaluronic acid a mucopolysaccharide
- one of the constituents of intercellular cement such as ceramides, fatty acids, cholesterol , etc., phospholipids or a derivative of these products.
- the concentration of hydrating compound varies from approximately 0.1% to approximately 30% by weight, preferably from approximately 0.5% to approximately
- composition according to the invention also comprises one or more preservatives, sun filters, excipients, stabilizing agents and / or perfumes such as those conventionally used in the cosmetics industry.
- the composition comprises, in percentage by weight relative to the total weight of the composition:
- the composition comprises, in percentage by weight relative to the total weight of the composition:
- the composition comprises, in percentage by weight relative to the total weight of the composition:
- the composition comprises, in percentage by weight relative to the total weight of the composition:
- compositions according to the invention are particularly well suited for cosmetic or dermatological use. As such, they can be in all the dosage forms usually used for these products, namely in particular aqueous, alcoholic or hydroalcoholic solution, water-in-oil or oil-in-water emulsion, composition in aerosol form, powder. , microgranulate, dispersion, lotion, ointment. These compositions are prepared according to the usual methods of the fields considered.
- compositions according to the invention notably constitute cleaning, protection, treatment or care compositions for the face, for the hands or for the body, for example day cream, night cream, make-up remover cream, anti-aging serum , body milk, cleansing milk, after-sun milk, cleansing milk, sun cream or oil, face or body gel, regenerating anti-wrinkle product, makeup composition, self-tanning composition, bath composition.
- the compositions according to the invention can also consist of solid preparations such as soaps or cleaning bars.
- compositions for the hair can also be used in various compositions for the hair, in particular shampoos, styling lotions, treating lotions, styling creams or gels, dye compositions, lotions or hair loss gels.
- composition comprising the following ingredients (in percentage by weight relative to the total weight of the composition) is prepared as described below.
- phase 1 After mixing the various constituents which compose it, phase 1 is heated to 80 ° C. with stirring in a melter.
- phase 2 The Carbomer contained in phase 2 is dispersed in water at 90 ° C with stirring then is poured into a mixer where it is neutralized by triethanolamine. The other constituents of phase 2 are then added and the mixture is brought to 80 ° C. with stirring.
- Phase 1 is poured onto phase 2 in the mixer with vigorous stirring, then the mixture is cooled with stirring.
- the various constituents of phase 3 are mixed and then phase 3 thus obtained, previously homogenized, is added at 60 ° C.
- phase 4 is prepared by mixing its constituents and then is introduced into the mixer at 40 ° C. Agitation is stopped when the product temperature reaches 25 ° C.
- a composition comprising the following ingredients (in percentage by weight relative to the total weight of the composition) is prepared as described below.
- phase 1 After mixing the various constituents which compose it, phase 1 is heated to 80 ° C. with stirring in a melter.
- phase 2 The gelling agents contained in phase 2 are dispersed in water at 90 ° C with stirring then the gel formed is poured into a mixer. The other constituents of phase 2 are added and the mixture is brought to 80 ° C. with stirring.
- Phase 1 is poured onto phase 2 in the mixer with vigorous stirring, then the mixture is cooled with stirring.
- Phase 3 previously prepared and homogenized is added at 60 ° C.
- phase 4 is prepared by mixing its constituents and then is introduced into the mixer at 40 ° C. Agitation is stopped when the product temperature reaches 25 ° C.
- composition comprising the following ingredients (in percentage by weight relative to the total weight of the composition) is prepared as described below.
- 0.25 mg / ml of collagen or 0.25 mg / ml of bovine serum albumin are incubated for 0, 4 and 10 days, with amounts of radioactive glucose of 0, 5, 50 and 200 mM at 37 ° C in a total volume of 4 ml of 50 mM phosphate buffer pH 7.4, in closed sterile tubes.
- the Schiff bases obtained by reaction between glucose and the amino residues of collagen or bovine serum albumin are reduced by adding 1 ml of a 2 mM solution of sodium borohydride tritiate.
- the reaction mixture obtained is then dialyzed at 4 ° C for 48 hours against distilled water, to remove the glucose and NaBH 4 not attached to the proteins.
- Radioactivity bound to proteins after dialysis is counted using a liquid scintillation counter.
- Tables I and II appearing in the appendix to this patent application illustrate the results. It appears from Table I that the fixation of glucose alone on serum albumin increases over time, passing from a measured radioactivity value of 4920 cpm at tO to a value of 11350 cpm after 10 days.
- lysine hydrochloride prevents the fixation of glucose, the radioactivity measured passing from a value of 4320 cpm at tO to a value of 4515 cpm after 10 days.
- compositions of the invention on the aging and elasticity of the skin.
- composition 1 The effect of composition 1 on the aging of the skin has been studied.
- the biomechanical properties of the skin are evaluated using a Dermal Torque Meter measuring device (company Diastron, Great Britain).
- This device includes a probe which allows torsion to be exerted on the skin with constant torque, the angle formed being measured as a function of time. The recording is also performed after the constraint is released.
- Composition 1 is applied to the forearm of 20 volunteers, the other forearm serving as a control.
- the dose of product applied to the skin corresponds to the normal dose for use and is between 1 and 2 mg / cm 2 .
- the measurements are carried out before application of the composition and after 15 days, 30 days and 45 days of daily treatment.
- the biomechanical properties are evaluated 12 to 15 hours after application of the composition.
- the viscoelastic behavior of the skin can be determined by the following characteristics.
- U V Viscoelastic extensibility of the skin corresponding to the plastic deformation of the skin between 0.05 and 30 seconds.
- U F Total extensibility of the skin including elastic extensibility (U E ) and viscoelastic extensibility (U V ). This total extensibility value is measured 30 seconds after the start of the application of a torque of 11mNm.
- composition 1 therefore makes it possible to significantly improve the viscoelastic properties of the skin: the skin is firmed while remaining supple and hydrated.
- composition 3 is tested under the same conditions as composition 1, after 15 days and 30 days of treatment.
- Table VI clearly shows a decrease in the elastic extensibility of the skin throughout the treatment.
- Table VII shows that the skin does not become firmer during the treatment and that simply a slowdown in the decrease in the firmness of the skin can be observed.
- Table VIII also shows that the skin does not become firmer, the values measured after 15 days and 30 days being very close to each other.
- composition 3 which does not contain an anti-glycation principle, produces only a negligible effect on the elasticity and firmness of the skin, in comparison with the results obtained with composition 1.
- composition 2 The anti-wrinkle effect of composition 2 was studied as follows. 20 volunteers aged 40 to 55 applied composition 2 to the face for four weeks, an untreated crow's feet serving as a control.
- Silicone impressions of crow's feet are taken before and after treatment, then observed under a confocal microscope.
- the densities of the surface microrelief of the skin (0-54 ⁇ m), medium wrinkles (56-110 ⁇ m) and deep wrinkles (112-400 ⁇ m) are measured on each impression. The results are expressed as a percentage change with respect to tO (before treatment) and with respect to the untreated control zone.
- the increase in microrelief constitutes a positive result generally indicating an improvement in the level of hydration of the skin.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cosmetics (AREA)
Abstract
Description
NOUVELLES COMPOSITIONS COSMETIQUES OU DERMATOLOGIQUES NEW COSMETIC OR DERMATOLOGICAL COMPOSITIONS
L'invention se rapporte à une nouvelle composition cosmétique ou dermatologique destinée à lutter contre le vieillissement de la peau et/ou à augmenter l'élasticité de la peau. The invention relates to a new cosmetic or dermatological composition intended to combat aging of the skin and / or to increase the elasticity of the skin.
Le vieillissement de la peau est un phénomène complexe, faisant intervenir de nombreuses réactions plus ou moins lentes et qui conduisent à une diminution de l'élasticité cutanée et à l'apparition de rides. The aging of the skin is a complex phenomenon, involving many more or less slow reactions and which lead to a decrease in skin elasticity and the appearance of wrinkles.
Ces modifications des propriétés biomécaniques sont principalement dues à l'évolution de deux des principales macromolécules du derme, le collagène et l'élastine. These changes in biomechanical properties are mainly due to the evolution of two of the main macromolecules of the dermis, collagen and elastin.
II est en effet connu que le collagène se renouvelle moins vite au couis du vieillissement et que le remplacement des fibres vieillies devient plus difficile, en raison notamment de l'apparition de liaisons croisées internes formant des ponts entre les fibres de collagène. It is in fact known that collagen is renewed more slowly at the time of aging and that the replacement of aged fibers becomes more difficult, in particular due to the appearance of internal cross links forming bridges between the collagen fibers.
Ces liaisons dont le nombre augmente avec l'âge participent au raidissement et à la rigidification des tissus qui sont des phénomènes caractéristiques d'un tissu vieillissant. These connections, the number of which increases with age, participate in the stiffening and stiffening of the tissues, which are characteristic phenomena of an aging tissue.
Il a été également montré que ces liaisons de pontage proviennent notamment d'une fixation du glucose sur le collagène, en particulier sur les résidus lysine et hydroxylysine de ce dernier (réf. 1). It has also been shown that these bridging bonds originate in particular from a fixation of glucose on the collagen, in particular on the lysine and hydroxylysine residues of the latter (ref. 1).
Cette fixation non enzymatique du glucose est connue sous le nom de glycation et a été mise en évidence depuis longtemps, notamment par les travaux de Maillard. Depuis, la fixation d'autres sucres, comme le fructose ou le ribose, a été également montrée. This non-enzymatic fixation of glucose is known under the name of glycation and has been demonstrated for a long time, in particular by the work of Maillard. Since then, the fixation of other sugars, such as fructose or ribose, has also been shown.
La fixation du glucose sur les protéines met en jeu une série de réactions parmi lesquelles la formation de bases de Schiff instables qui se réarrangent en des produits plus stables, connus sous le nom de produits d'Amadori. Au cours du temps, ces produits d'Amadori peuvent alors réagir avec une variété de molécules, pour donner finalement après réarrangement des structures irréversibles. Dans le cas du glucose, des expériences ont montré que l'un des produits irréversibles finalement formés est le [2-(2-furoyl)-4(5)-(2-furanyl)-1H- imidazole]. The binding of glucose to proteins involves a series of reactions including the formation of unstable Schiff bases which rearrange into more stable products, known as Amadori products. Over time, these Amadori products can then react with a variety of molecules, to finally give irreversible structures after rearrangement. In the case of glucose, experiments have shown that one of the irreversible products ultimately formed is [2- (2-furoyl) -4 (5) - (2-furanyl) -1H- imidazole].
Ce produit est brun jaunâtre et fluorescent. This product is yellowish brown and fluorescent.
Dans le cas du glucose, une corrélation a pu être établie entre l'augmentation du taux de glycation et l'augmentation de la résistance à la traction du collagène (réf. 2) ainsi qu'une diminution de sa solubilité (réf. 3), établissant le rôle néfaste de ces produits de glycation dans les propriétés mécaniques du collagène. In the case of glucose, a correlation has been established between the increase in the glycation rate and the increase in the tensile strength of collagen (ref. 2) as well as a decrease in its solubility (ref. 3) , establishing the harmful role of these glycation products in the mechanical properties of collagen.
II est connu d'autre part que la fixation du glucose sur les protéines entraîne, en présence d'oxygène, la formation de radicaux libres (réf. 4). Les effets destructeurs des radicaux libres sur les différents constituants de la peau sont bien connus : peroxydation des lipides, coupure des protéines et des glycosaminoglycannes, pontage entre résidus tyrosine et protéines, etc. Du fait de ces dégradations, l'apparition de radicaux libres constitue également un facteur de vieillissement du tissu cutané. It is also known that the fixation of glucose on proteins leads, in the presence of oxygen, to the formation of free radicals (ref. 4). The destructive effects of free radicals on the various constituents of the skin are well known: lipid peroxidation, cutting of proteins and glycosaminoglycans, bridging between tyrosine residues and proteins, etc. Due to these degradations, the appearance of free radicals also constitutes an aging factor of the skin tissue.
Enfin, si la glycation du collagène se déroule en milieu oxydant, d'autres types de pontages sont également formés. Par exemple, la fructolysine est elle-même dégradée en N-(carboxyméthyl) lysine ou est transformée, après réaction avec un résidu arginine, pour donner finalement la pentosidine. Finally, if the glycation of collagen takes place in an oxidizing medium, other types of bypass are also formed. For example, fructolysine is itself degraded into N- (carboxymethyl) lysine or is transformed, after reaction with an arginine residue, to finally give pentosidine.
Ces pontages résultant d'une glycoxy dation des protéines augmentent également avec l'âge chez l'homme (réf. 5). These bypasses resulting from protein glycoxyation also increase with age in humans (ref. 5).
Il a été alors proposé d'utiliser des substances empêchant les produits d'Amadori de se réarranger au cours du temps en produits irréversibles. Il a été montré en particulier que l'aminoguanidine diminue la réticulation des protéines contenues dans les parois artérielles de sujets diabétiques. L'aminoguanidine agit en bloquant la transformation des produits d'Amadori résultant du réarrangement du glucose et d'une protéine en [2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole] (réf. 6). En outre, il est connu depuis longtemps que les élastases sont les enzymes responsables de la dégradation de l'élastine par hydrolyse (réf. 7) et que par conséquent les élastases contribuent également à la dégradation des propriétés élastiques de la peau. It was then proposed to use substances preventing Amadori products from rearranging over time into irreversible products. It has been shown in particular that aminoguanidine decreases the crosslinking of proteins contained in the arterial walls of diabetic subjects. Aminoguanidine works by blocking the transformation of Amadori products resulting from the rearrangement of glucose and a protein into [2- (2-furoyl) -4 (5) - (2-furanyl) -1H-imidazole] (ref . 6). In addition, it has long been known that elastases are the enzymes responsible for the degradation of elastin by hydrolysis (ref. 7) and that therefore elastases also contribute to the degradation of the elastic properties of the skin.
Deux types d'élastases peuvent être rencontrées dans la peau. Tout d'abord, l'elastase leucocytaire est libérée par les polymorphonucléaires suite à l'exposition de la peau à une tension ou un stress, notamment un rayonnement ultraviolet, une pollution, une infection, etc. (réf. 8). D'autre part des élastases appartenant à la classe de métalloprotéases sont synthétisées par les fibroblastes du derme et ce de façon croissante avec l'âge (réf. 9). Two types of elastases can be found in the skin. First of all, the leukocyte elastase is released by polymorphonuclear cells following the exposure of the skin to tension or stress, in particular ultraviolet radiation, pollution, infection, etc. (ref. 8). On the other hand, elastases belonging to the class of metalloproteases are synthesized by fibroblasts of the dermis and this in an increasing manner with age (ref. 9).
Le pontage du collagène par glycation et la rigidification des fibres qui en résulte d'une part, la destruction des fibres d'élastine sous l'effet des élastases d'autre part, sont deux phénomènes dont la conjuguaison provoque une perte d'élasticité du derme qui conduit à la formation de rides et de ridules. Il importe donc d'agir simultanément sur les deux phénomènes pour restaurer une élasticité cutanée convenable et combattre l'apparition des rides. The bridging of collagen by glycation and the stiffening of the fibers which results therefrom on the one hand, the destruction of the elastin fibers under the effect of the elastases on the other hand, are two phenomena whose conjugation causes a loss of elasticity of the dermis which leads to the formation of wrinkles and fine lines. It is therefore important to act simultaneously on the two phenomena to restore adequate skin elasticity and combat the appearance of wrinkles.
Bien que l'utilisation de composés tels que l'aminoguanidine montre déjà une action anti-glycation, les Inventeurs de la présente demande de brevet ont cherché à améliorer les résultats obtenus. Although the use of compounds such as aminoguanidine already shows an anti-glycation action, the inventors of the present patent application have sought to improve the results obtained.
Le but principal de la présente invention est donc de fournir une nouvelle composition cosmétique ou dermatologique à action conjuguée antiglycation et anti-élastase améliorées et permettant d'éviter la formation de radicaux libres. The main aim of the present invention is therefore to provide a new cosmetic or dermatological composition with improved anti-glycation and anti-elastase combined action and making it possible to avoid the formation of free radicals.
Un autre but de la présente invention concerne l'utilisation de composés anti-glycation et de composés anti-élastase en vue de la préparation d'une composition cosmétique. Another object of the present invention relates to the use of anti-glycation compounds and anti-elastase compounds for the preparation of a cosmetic composition.
La composition selon la présente invention, en vue de lutter contre le vieillissement et/ou d'augmenter l'élasticité de la peau, se caractérise en ce qu'elle comprend un premier principe actif choisi parmi les composés naturels ou synthétiques capables d'inhiber la formation de produits d'Amadori par réaction non enzymatique de sucres, notamment de glucose, avec le collagène de la peau, ledit premier principe actif étant constitué d'un composé unique ou d'un mélange de plusieurs composés; et en ce qu'elle comprend un second principe actif choisi parmi les composés naturels ou synthétiques capables d'inhiber l'activité des élastases de la peau, ledit second principe actif étant constitué d'un composé unique ou d'un mélange de plusieurs composés. The composition according to the present invention, with a view to combating aging and / or increasing the elasticity of the skin, is characterized in that it comprises a first active principle chosen from natural or synthetic compounds capable of inhibiting the formation of Amadori products by reaction non-enzymatic of sugars, in particular glucose, with the collagen of the skin, said first active principle consisting of a single compound or of a mixture of several compounds; and in that it comprises a second active principle chosen from natural or synthetic compounds capable of inhibiting the activity of skin elastases, said second active principle consisting of a single compound or of a mixture of several compounds .
La présente invention résulte de la découverte surprenante que certains produits peuvent bloquer la glycation des protéines à un stade antérieur à celui de la formation de produits d'Amadori. The present invention results from the surprising discovery that certain products can block the glycation of proteins at a stage prior to that of the formation of Amadori products.
De cette façon, le mécanisme de la dégradation du collagène par glycation, peut être bloqué de façon encore plus précoce qu'auparavant et permet ainsi d'obtenir de meilleurs résultats sur l'élasticité de la peau. In this way, the mechanism of degradation of collagen by glycation, can be blocked even earlier than before and thus allows to obtain better results on the elasticity of the skin.
Selon l'invention, le premier principe actif est choisi notamment parmi les acides aminés, de préférence basiques, notamment la lysine, l'arginine, l'histidine; les peptides, de préférence ceux contenant un ou plusieurs acides aminés basiques; l'allantoïne; la vitamine E; la vitamine B1; la vitamine B6; la thiourée; le dithiothréitol; les dérivés du silicium organique et/ou les dérivés de ces produits. According to the invention, the first active principle is chosen in particular from amino acids, preferably basic, in particular lysine, arginine, histidine; peptides, preferably those containing one or more basic amino acids; allantoin; vitamin E; vitamin B 1 ; vitamin B 6 ; thiourea; dithiothreitol; organic silicon derivatives and / or derivatives of these products.
Selon une forme de réalisation préférée de la présente invention, les dérivés d'acides aminés comprennent notamment le pyrrolidone carboxylate de lysine, le pyrrolidone carboxylate d'arginine, l'aspartate d'arginine. According to a preferred embodiment of the present invention, the amino acid derivatives include in particular lysine pyrrolidone carboxylate, arginine pyrrolidone carboxylate, arginine aspartate.
Selon l'invention, le second principe actif est choisi parmi les composés capables de bloquer l'action de l'élastase leucocytaire et/ou des élastases synthétisées par les fibroblastes. Il est choisi notamment parmi les extraits végétaux riches en tanins, en anthocyanosides, les oligomères procyanidoliques, l'extrait de soja, notamment les extraits protéiques de soja, l'α-1-anti-trypsine, les extraits d'algues, notamment les hydrolysats de protéines d'algue verte et les extraits de micro algues, les polysaccharides, notamment les polysaccharides sulfatés, les céramides. Selon l'invention, la composition comprend, en pourcentage en poids par rapport au poids total de la composition, d'environ 0,01 % à environ 50 % en poids dudit premier principe actif, de préférence d'environ 0,1 % à environ 10 % en poids, de façon plus préférée d'environ 0.2 % à environ 5 % en poids et d'environ 0,01 % à environ 50 % en poids dudit second principe actif, de préférence d'environ 0,1 % à environ 10 % en poids, de façon plus préférée d'environ 0,5 % à environ 5 % en poids. According to the invention, the second active principle is chosen from compounds capable of blocking the action of leukocyte elastase and / or elastases synthesized by fibroblasts. It is chosen in particular from plant extracts rich in tannins, in anthocyanosides, procyanidolic oligomers, soy extract, in particular soy protein extracts, α-1-anti-trypsin, algae extracts, especially hydrolysates of green algae proteins and micro algae extracts, polysaccharides, in particular sulfated polysaccharides, ceramides. According to the invention, the composition comprises, as a percentage by weight relative to the total weight of the composition, from approximately 0.01% to approximately 50% by weight of said first active principle, preferably from approximately 0.1% to about 10% by weight, more preferably from about 0.2% to about 5% by weight and from about 0.01% to about 50% by weight of said second active ingredient, preferably from about 0.1% to about 10% by weight, more preferably from about 0.5% to about 5% by weight.
Selon une forme de réalisation préférée de la présente invention, la composition comprend de plus au moins un composé naturel ou synthétique activateur de la synthèse du collagène, notamment un extrait de Centella asiatica, de l'acide ascorbique, des peptides, des β-glucanes ou des extraits d'algues ou d'avoine en contenant, ou les dérivés de ces produits. According to a preferred embodiment of the present invention, the composition further comprises at least one natural or synthetic compound activating the synthesis of collagen, in particular an extract of Centella asiatica, ascorbic acid, peptides, β-glucans or seaweed or oat extracts containing them, or derivatives of these products.
Avantageusement, la concentration en composé activateur de la synthèse du collagène varie d'environ 0,01% à environ 10 % en poids, de préférence d'environ 0,05% à environ 5 % en poids par rapport au poids total de la composition. Advantageously, the concentration of compound activating the synthesis of collagen varies from approximately 0.01% to approximately 10% by weight, preferably from approximately 0.05% to approximately 5% by weight relative to the total weight of the composition. .
Selon une autre forme de réalisation préférée de la présente invention, la composition comprend de plus au moins un composé naturel ou synthétique capable d'empêcher la production de radicaux libres, améliorant ainsi les propriétés inhibitrices de la formation de radicaux libres du premier principe actif. According to another preferred embodiment of the present invention, the composition further comprises at least one natural or synthetic compound capable of preventing the production of free radicals, thus improving the inhibitory properties of the formation of free radicals of the first active principle.
On citera à titre illustratif de composés capables d'empêcher la formation de radicaux libres utilisables dans le cadre de la présente demande de brevet la vitamine E ou ses esters, la vitamine C, les extraits de plantes riches en flavonoïdes ou polyphénols, telles que le Ginkgo biloba, le thé vert, le chardonmarie, etc., l'acide caféique, l'acide férulique, le glutathion, les enzymes telles que la superoxyde dismutase, la glutathion reductase et la glutathion peroxydase, les sels de zinc, le mannitol ou un dérivé de ces produits. Mention will be made, by way of illustration of compounds capable of preventing the formation of free radicals which can be used in the context of the present patent application, vitamin E or its esters, vitamin C, plant extracts rich in flavonoids or polyphenols, such as Ginkgo biloba, green tea, thistle, etc., caffeic acid, ferulic acid, glutathione, enzymes such as superoxide dismutase, glutathione reductase and glutathione peroxidase, zinc salts, mannitol or a derivative of these products.
Avantageusement, la concentration en composé inhibant la production de radicaux libres varie d'environ 0,01 % à environ 20% en poids, de préférence d'environ 0,1 % à environ 5 % en poids par rapport au poids total de la composition. Advantageously, the concentration of compound inhibiting the production of free radicals varies from approximately 0.01% to approximately 20% by weight, preferably from about 0.1% to about 5% by weight relative to the total weight of the composition.
Selon une autre forme de réalisation préférée de la présente invention, la composition comprend de plus au moins un composé naturel ou synthétique hydratant, notamment les polyols, un constituant du facteur d'hydratation naturel According to another preferred embodiment of the present invention, the composition further comprises at least one natural or synthetic hydrating compound, in particular polyols, a constituent of the natural hydration factor
(Natural Moisturing Factor ou NMF) tel que l'urée, un acide aminé, un extrait de miel, de l'acide hyaluronique, un mucopolysaccharide, l'un des constituants du ciment intercellulaire tel que les ceramides, les acides gras, le cholestérol, etc., des phospholipides ou un dérivé de ces produits. (Natural Moisturing Factor or NMF) such as urea, an amino acid, a honey extract, hyaluronic acid, a mucopolysaccharide, one of the constituents of intercellular cement such as ceramides, fatty acids, cholesterol , etc., phospholipids or a derivative of these products.
Avantageusement, la concentration en composé hydratant varie d'environ 0,1 % à environ 30 % en poids, de préférence d'environ 0,5 % à environ Advantageously, the concentration of hydrating compound varies from approximately 0.1% to approximately 30% by weight, preferably from approximately 0.5% to approximately
10 % en poids par rapport au poids total de la composition. 10% by weight relative to the total weight of the composition.
Avantageusement, la composition selon l'invention comprend également un ou plusieurs agents conservateurs, filtres solaires, excipients, agents stabilisants et/ou parfums tels que ceux conventionnellement utilisés dans l'industrie des cosmétiques. Advantageously, the composition according to the invention also comprises one or more preservatives, sun filters, excipients, stabilizing agents and / or perfumes such as those conventionally used in the cosmetics industry.
Selon une forme de réalisation préférée de la présente invention, la composition comprend, en pourcentage en poids par rapport au poids total de la composition : According to a preferred embodiment of the present invention, the composition comprises, in percentage by weight relative to the total weight of the composition:
- d'environ 0,1 % à environ 10 % de pyrrolidone carboxylate de lysine; - from about 0.1% to about 10% of lysine pyrrolidone carboxylate;
- d'environ 0,1 % à environ 5 % d'un extrait de soja possédant une activité anti-élastase ; - from about 0.1% to about 5% of a soy extract having anti-elastase activity;
- d'environ 0,1 % à environ 5 % d'un mélange de plantes à activité anti-élastase. - from about 0.1% to about 5% of a mixture of plants with anti-elastase activity.
Selon une autre forme de réalisation préférée de la présente invention, la composition comprend, en pourcentage en poids par rapport au poids total de la composition : According to another preferred embodiment of the present invention, the composition comprises, in percentage by weight relative to the total weight of the composition:
- d'environ 0,1 % à environ 10 % d'aspartate d'arginine; - from about 0.1% to about 10% of arginine aspartate;
- d'environ 0,01 % à environ 2% d'oligomères procyanidoliques. Selon une autre forme de réalisation préférée de la présente invention, la composition comprend, en pourcentage en poids par rapport au poids total de la composition : - from approximately 0.01% to approximately 2% of procyanidolic oligomers. According to another preferred embodiment of the present invention, the composition comprises, in percentage by weight relative to the total weight of the composition:
- d'environ 0,1 % à environ 5 % de L-histidine; - from about 0.1% to about 5% of L-histidine;
- d'environ 0,1 % à environ 5 % d'un extrait de soja à activité anti- élastase; - from about 0.1% to about 5% of a soy extract with anti-elastase activity;
d'environ 0,1 % à environ 5 % d'un extrait d'algues à effet anti- elastase. from about 0.1% to about 5% of an algae extract with anti-elastase effect.
Selon une autre forme de réalisation préférée de la présente invention, la composition comprend, en pourcentage en poids par rapport au poids total de la composition : According to another preferred embodiment of the present invention, the composition comprises, in percentage by weight relative to the total weight of the composition:
- d'environ 0,1 % à environ 5 % de pyrrolidone carboxylate de L- lysine; - from about 0.1% to about 5% of L-lysine pyrrolidone carboxylate;
- d'environ 0,1 % à environ 5 % d'aspartate d'arginine; - from about 0.1% to about 5% of arginine aspartate;
- d'environ 0,1 % à environ 10 % d'un extrait de soja à effet anti- élastase. - from about 0.1% to about 10% of a soy extract with anti-elastase effect.
Les compositions selon l'invention sont particulièrement bien adaptées pour un usage cosmétique ou dermatologique. A ce titre, elles peuvent se présenter sous toutes les formes galéniques habituellement utilisées pour ces produits, à savoir notamment solution aqueuse, alcoolique ou hydroalcoolique, émulsion eau-dans-huile ou huile-dans-eau, composition sous forme d'aérosol, poudre, microgranulé, dispersion, lotion, pommade. Ces compositions sont préparées selon les méthodes usuelles des domaines considérés. The compositions according to the invention are particularly well suited for cosmetic or dermatological use. As such, they can be in all the dosage forms usually used for these products, namely in particular aqueous, alcoholic or hydroalcoholic solution, water-in-oil or oil-in-water emulsion, composition in aerosol form, powder. , microgranulate, dispersion, lotion, ointment. These compositions are prepared according to the usual methods of the fields considered.
Les compositions selon l'invention constituent notamment des compositions de nettoyage, de protection, de traitement ou de soin pour le visage, pour les mains ou pour le corps, par exemple crème de jour, crème de nuit, crème démaquillante, sérum anti-âge, lait corporel, lait de démaquillage, lait après-soleil, lait de nettoyage, crème ou huile solaire, gel pour le visage ou pour le corps, produit anti-rides régénérant, composition de maquillage, composition autobronzante, composition pour le bain. Les compositions selon l'invention peuvent en outre consister en des préparations solides telles que savons ou pains de nettoyage. The compositions according to the invention notably constitute cleaning, protection, treatment or care compositions for the face, for the hands or for the body, for example day cream, night cream, make-up remover cream, anti-aging serum , body milk, cleansing milk, after-sun milk, cleansing milk, sun cream or oil, face or body gel, regenerating anti-wrinkle product, makeup composition, self-tanning composition, bath composition. The compositions according to the invention can also consist of solid preparations such as soaps or cleaning bars.
Elles peuvent également être utilisées dans diverses compositions pour les cheveux, notamment des shampooings, des lotions de mise en plis, des lotions traitantes, des crèmes ou gels coiffants, des compositions de teintures, des lotions ou gels antichute. They can also be used in various compositions for the hair, in particular shampoos, styling lotions, treating lotions, styling creams or gels, dye compositions, lotions or hair loss gels.
Des avantages et caractéristiques supplémentaires de la présente invention apparaîtront encore à la lumière de la description plus détaillée qui suit de modes de réalisation particuliers de l'invention, donnés à titre illustratif et non limitatif. Additional advantages and characteristics of the present invention will become apparent in the light of the more detailed description which follows of particular embodiments of the invention, given by way of illustration and not limitation.
Exemple 1. Example 1.
Préparation d'une crème pour le visage Preparation of a face cream
Une composition comprenant les ingrédients suivants (en pourcentage en poids par rapport au poids total de la composition) est préparée comme décrit ci-dessous. A composition comprising the following ingredients (in percentage by weight relative to the total weight of the composition) is prepared as described below.
Préparation : Preparation:
Après mélange des différents constituants qui la compose, la phase 1 est chauffée à 80°C sous agitation dans un fondoir. After mixing the various constituents which compose it, phase 1 is heated to 80 ° C. with stirring in a melter.
Le Carbomer contenu dans la phase 2 est dispersé dans l'eau à 90°C sous agitation puis est versé dans un mélangeur où il est neutralisé par la triéthanolamine. Les autres constituants de la phase 2 sont alors ajoutés et le mélange est porté sous agitation à 80°C. The Carbomer contained in phase 2 is dispersed in water at 90 ° C with stirring then is poured into a mixer where it is neutralized by triethanolamine. The other constituents of phase 2 are then added and the mixture is brought to 80 ° C. with stirring.
La phase 1 est versée sur la phase 2 dans le mélangeur sous forte agitation puis le mélange est refroidi sous agitation. Les différents constituants de la phase 3 sont mélangés puis la phase 3 ainsi obtenue, préalablement homogénéisée, est ajoutée à 60°C. Enfin, la phase 4 est préparée par mélange de ses constituants puis est introduite dans le mélangeur à 40°C. L'agitation est stoppée quand la température du produit atteint 25°C. Phase 1 is poured onto phase 2 in the mixer with vigorous stirring, then the mixture is cooled with stirring. The various constituents of phase 3 are mixed and then phase 3 thus obtained, previously homogenized, is added at 60 ° C. Finally, phase 4 is prepared by mixing its constituents and then is introduced into the mixer at 40 ° C. Agitation is stopped when the product temperature reaches 25 ° C.
Exemple 2. Example 2.
Préparation d'une crème pour la nuit. Une composition comprenant les ingrédients suivants (en pourcentage en poids par rapport au poids total de la composition) est préparée comme décrit ci-dessous. Preparation of a cream for the night. A composition comprising the following ingredients (in percentage by weight relative to the total weight of the composition) is prepared as described below.
Préparation : Preparation:
Après mélange des différents constituants qui la compose, la phase 1 est chauffée à 80°C sous agitation dans un fondoir. After mixing the various constituents which compose it, phase 1 is heated to 80 ° C. with stirring in a melter.
Les gélifiants contenus dans la phase 2 sont dispersés dans l'eau à 90°C sous agitation puis le gel formé est versé dans un mélangeur. Les autres constituants de la phase 2 sont ajoutés et le mélange est porté sous agitation à 80°C. The gelling agents contained in phase 2 are dispersed in water at 90 ° C with stirring then the gel formed is poured into a mixer. The other constituents of phase 2 are added and the mixture is brought to 80 ° C. with stirring.
La phase 1 est versée sur la phase 2 dans le mélangeur sous forte agitation puis le mélange est refroidi sous agitation. La phase 3 préalablement préparée et homogénéisée est ajoutée à 60°C. Enfin, la phase 4 est préparée par mélange de ses constituants puis est introduite dans le mélangeur à 40°C. L'agitation est stoppée quand la température du produit atteint 25°C. Phase 1 is poured onto phase 2 in the mixer with vigorous stirring, then the mixture is cooled with stirring. Phase 3 previously prepared and homogenized is added at 60 ° C. Finally, phase 4 is prepared by mixing its constituents and then is introduced into the mixer at 40 ° C. Agitation is stopped when the product temperature reaches 25 ° C.
Exemple 3. Example 3.
Préparation d'une crème pour le visage. Preparation of a face cream.
Une composition comprenant les ingrédients suivants (en pourcentage en poids par rapport au poids total de la composition) est préparée comme décrit ci-dessous. A composition comprising the following ingredients (in percentage by weight relative to the total weight of the composition) is prepared as described below.
Le mode de préparation est identique à celui décrit dans l'exemple 1. Résultats expérimentaux, The method of preparation is identical to that described in Example 1. Experimental results,
a) Mise en évidence de l'action anti-glycation. a) Demonstration of the anti-glycation action.
Dans cette expérience, la fixation du glucose sur le collagène et la sérum albumine bovine est étudiée. In this experiment, the binding of glucose to collagen and bovine serum albumin is studied.
Pour ce faire, 0,25 mg/ml de collagène ou 0,25 mg/ml de sérum albumine bovine sont mis à incuber pendant 0, 4 et 10 jours, avec des quantités de glucose radioactif de 0, 5, 50 et 200 mM à 37°C dans un volume total de 4 ml de tampon phosphate 50 mM pH 7,4, dans des tubes stériles bouchés. A l'issue de la période d'incubation, les bases de Schiff obtenues par réaction entre le glucose et les résidus aminés du collagène ou de la sérum albumine bovine sont réduites par addition de 1 ml d'une solution à 2mM de borohydrure de sodium tritié. Le mélange réactionnel obtenu est ensuite dialyse à 4°C pendant 48 heures contre l'eau distillée , pour éliminer le glucose et le NaBH4 non fixés sur les protéines. To do this, 0.25 mg / ml of collagen or 0.25 mg / ml of bovine serum albumin are incubated for 0, 4 and 10 days, with amounts of radioactive glucose of 0, 5, 50 and 200 mM at 37 ° C in a total volume of 4 ml of 50 mM phosphate buffer pH 7.4, in closed sterile tubes. At the end of the incubation period, the Schiff bases obtained by reaction between glucose and the amino residues of collagen or bovine serum albumin are reduced by adding 1 ml of a 2 mM solution of sodium borohydride tritiate. The reaction mixture obtained is then dialyzed at 4 ° C for 48 hours against distilled water, to remove the glucose and NaBH 4 not attached to the proteins.
La radioactivité liée aux protéines après dialyse est comptée à l'aide d'un compteur à scintillation liquide. Radioactivity bound to proteins after dialysis is counted using a liquid scintillation counter.
La même expérience est menée en parallèle en ajoutant au collagène ou à la sérum albumine bovine de départ 200 mM de chlorhydrate de L-lysine. The same experiment is carried out in parallel by adding 200 mM of L-lysine hydrochloride to the starting collagen or bovine albumin serum.
Les tableaux I et II figurant en annexe de la présente demande de brevet illustrent les résultats. Il apparaît du tableau I que la fixation du glucose seul sur la sérum albumine augmente au cours du temps, passant d'une valeur de radioactivité mesurée de 4920 cpm à tO à une valeur de 11350 cpm après 10 jours. Tables I and II appearing in the appendix to this patent application illustrate the results. It appears from Table I that the fixation of glucose alone on serum albumin increases over time, passing from a measured radioactivity value of 4920 cpm at tO to a value of 11350 cpm after 10 days.
L'addition de chlrorhydrate de lysine empêche la fixation du glucose, la radioactivité mesurée passant d'une valeur de 4320 cpm à tO à une valeur de 4515 cpm après 10 jours. The addition of lysine hydrochloride prevents the fixation of glucose, the radioactivity measured passing from a value of 4320 cpm at tO to a value of 4515 cpm after 10 days.
Les résultats sont identiques dans le tableau II qui montre que l'addition de chlorhydrate de lysine empêche la fixation du glucose sur le collagène. The results are identical in Table II which shows that the addition of lysine hydrochloride prevents the binding of glucose to the collagen.
Les résultats obtenus montrent donc que, dans les tubes ne contenant pas de L-lysine, le glucose se fixe sur le collagène ou sur la sérum albumine bovine alors que dans les tubes où de la L-lysine a été ajoutée aux protéines, la fixation du glucose sur le collagène ou sur la sérum albumine bovine est complètement inhibée. The results obtained therefore show that, in the tubes not containing L-lysine, the glucose fixes itself on the collagen or on the bovine serum albumin whereas in the tubes where L-lysine was added to the proteins, the fixation glucose on collagen or bovine serum albumin is completely inhibited.
b) Effets des compositions de l'invention sur le vieillissement et l'élasticité de la peau. b) Effects of the compositions of the invention on the aging and elasticity of the skin.
L'effet de la composition 1 sur le vieillissement de la peau a été étudié. The effect of composition 1 on the aging of the skin has been studied.
Dans ce test, les caractéristiques viscoélastiques de la peau ont été mesurées. In this test, the viscoelastic characteristics of the skin were measured.
Les propriétés biomécaniques de la peau sont évaluées en utilisant un appareil de mesure Dermal Torque Meter, (société Diastron, Grande-Bretagne). Cet appareil comporte une sonde qui permet d'exercer une torsion sur la peau avec un torque constant, l'angle formé étant mesuré en fonction du temps. L'enregistrement est également réalisé après relâchement de la contrainte. The biomechanical properties of the skin are evaluated using a Dermal Torque Meter measuring device (company Diastron, Great Britain). This device includes a probe which allows torsion to be exerted on the skin with constant torque, the angle formed being measured as a function of time. The recording is also performed after the constraint is released.
La composition 1 est appliquée sur l'avant-bras de 20 volontaires, l'autre avant-bras servant de témoin. La dose de produit appliquée sur la peau correspond à la dose normale d'utilisation et est comprise entre 1 et 2 mg/cm2. Composition 1 is applied to the forearm of 20 volunteers, the other forearm serving as a control. The dose of product applied to the skin corresponds to the normal dose for use and is between 1 and 2 mg / cm 2 .
Les mesures sont effectuées avant application de la composition et après 15 jours, 30 jours et 45 jours de traitement quotidien. The measurements are carried out before application of the composition and after 15 days, 30 days and 45 days of daily treatment.
Les propriétés biomécaniques sont évaluées 12 à 15 heures après application de la composition. The biomechanical properties are evaluated 12 to 15 hours after application of the composition.
Le comportement viscoélastique de la peau peut être déterminé au moyen des caractéristiques suivantes. The viscoelastic behavior of the skin can be determined by the following characteristics.
UE : Déviation angulaire instantanée (à 0,05 seconde) correspondant à l'extensibilité élastique de la peau soumise à un torque constant de 1 lmNm. U E : Instantaneous angular deviation (at 0.05 seconds) corresponding to the elastic extensibility of the skin subjected to a constant torque of 1 lmNm.
UV : Extensibilité viscoélastique de la peau correspondant à la déformation plastique de la peau entre 0,05 et 30 secondes. U V : Viscoelastic extensibility of the skin corresponding to the plastic deformation of the skin between 0.05 and 30 seconds.
UF : Extensibilité totale de la peau intégrant l'extensibilité élastique (UE) et l'extensibilité viscoélastique (UV). Cette valeur d'extensibilité totale est mesurée 30 secondes après le début de l'application d'un torque de 11mNm. U F : Total extensibility of the skin including elastic extensibility (U E ) and viscoelastic extensibility (U V ). This total extensibility value is measured 30 seconds after the start of the application of a torque of 11mNm.
UR : Rétablissement élastique immédiat après arrêt de la torsion appliquée sur la peau. U R : Immediate elastic recovery after the torsion applied to the skin has stopped.
Les résultats, exprimés par rapport au temps et au témoin, sont donnés dans les tableaux III à V figurant en annexe de la présente demande de brevet. The results, expressed in relation to time and to the control, are given in Tables III to V appearing in the appendix to this patent application.
En se référant au tableau III, il apparaît que l'extensibilité élastique (UE) de la peau est sensiblement améliorée au cours du traitement, atteignant une augmentation de + 41.3 % au bout de 45 jours. Referring to Table III, it appears that the elastic extensibility (U E ) of the skin is significantly improved during the treatment, reaching an increase of + 41.3% after 45 days.
En se référant maintenant au tableau IV, il apparaît que le rapport UV/UE diminue, signifiant que la fermeté cutanée lors de l'application de la contrainte est également améliorée, diminuant jusqu'à une valeur de - 24,2 % au bout de 45 jours. En se référant enfin au tableau V, il apparaît que la composition 1 améliore également la fermeté cutanée après arrêt de la contrainte, le rapport UR/UF augmentant de 12,4 % au bout de 45 jours. Referring now to Table IV, it appears that the U V / U E ratio decreases, signifying that the skin firmness during the application of the stress is also improved, decreasing to a value of - 24.2% at after 45 days. Referring finally to Table V, it appears that composition 1 also improves skin firmness after stress is stopped, the U R / U F ratio increasing by 12.4% after 45 days.
L'utilisation quotidienne de la composition 1 permet donc d'améliorer de façon importante les propriétés viscoélastiques de la peau : la peau est raffermie tout en restant souple et hydratée. The daily use of composition 1 therefore makes it possible to significantly improve the viscoelastic properties of the skin: the skin is firmed while remaining supple and hydrated.
A titre de comparaison, la composition 3 est testée dans les mêmes conditions que la composition 1, après 15 jours et 30 jours de traitement. By way of comparison, composition 3 is tested under the same conditions as composition 1, after 15 days and 30 days of treatment.
Les résultats expérimentaux sont illustrés dans les tableaux VI, VII et VIII figurant en annexe de la présente demande de brevet. The experimental results are illustrated in Tables VI, VII and VIII appearing in the appendix to this patent application.
Le tableau VI montre clairement une diminution de l'extensibilité élastique de la peau tout au long du traitement. Table VI clearly shows a decrease in the elastic extensibility of the skin throughout the treatment.
Le tableau VII met en évidence que la peau ne devient pas plus ferme au cours du traitement et que simplement un ralentissement de la diminution de la fermeté de la peau peut être observée. Table VII shows that the skin does not become firmer during the treatment and that simply a slowdown in the decrease in the firmness of the skin can be observed.
Le tableau VIII montre également que la peau ne devient pas plus ferme, les valeurs mesurées au bout de 15 jours et de 30 jours étant très proches l'une de l'autre. Table VIII also shows that the skin does not become firmer, the values measured after 15 days and 30 days being very close to each other.
Il apparaît donc que la composition 3, qui ne contient pas de principe anti-glycation, ne produit qu'un effet négligeable sur l'élasticité et la fermeté de la peau, en comparaison avec les résultats obtenus avec la composition 1. It therefore appears that composition 3, which does not contain an anti-glycation principle, produces only a negligible effect on the elasticity and firmness of the skin, in comparison with the results obtained with composition 1.
c) Effet anti-rides des compositions de l'invention. c) Anti-wrinkle effect of the compositions of the invention.
L'effet anti-rides de la composition 2 a été étudié de la façon suivante. 20 volontaires âgés de 40 à 55 ans ont appliqué la composition 2 sur le visage pendant quatre semaines, une patte d'oie non traitée servant de témoin. The anti-wrinkle effect of composition 2 was studied as follows. 20 volunteers aged 40 to 55 applied composition 2 to the face for four weeks, an untreated crow's feet serving as a control.
Des empreintes en silicone des pattes d'oie sont prises avant et après traitement, puis sont observées au microscope confocal. Silicone impressions of crow's feet are taken before and after treatment, then observed under a confocal microscope.
Les densités du microrelief de surface de la peau (0-54 μm), des rides moyennes (56-110 μm) et des rides profondes (112-400 μm) sont mesurées sur chaque empreinte. Les résultats sont exprimés en pourcentage de variation par rapport à tO (avant traitement) et par rapport à la zone témoin non traitée. The densities of the surface microrelief of the skin (0-54 μm), medium wrinkles (56-110 μm) and deep wrinkles (112-400 μm) are measured on each impression. The results are expressed as a percentage change with respect to tO (before treatment) and with respect to the untreated control zone.
Les résultats (moyenne sur 20 sujets) ont été les suivants : The results (average over 20 subjects) were as follows:
- Augmentation du microrelief : 6 %; - Increase in microrelief: 6%;
- Diminution des rides moyennes : 6 %; - Reduction of medium wrinkles: 6%;
- Diminution des rides profondes : 59 %. - Reduction of deep wrinkles: 59%.
L'augmentation du microrelief constitue un résultat positif témoignant généralement d'une amélioration du niveau d'hydratation de la peau. The increase in microrelief constitutes a positive result generally indicating an improvement in the level of hydration of the skin.
Il va de soi que la présente invention ne se limite pas aux formes de réalisation préférées qui viennent d'être décrites dans ce qui précède, mais en embrasse au contraire toutes les variantes. It goes without saying that the present invention is not limited to the preferred embodiments which have just been described in the foregoing, but on the contrary embraces all variants.
L'homme du métier pourra en effet apporter des modifications à la présente invention, sans pour autant sortir du cadre de ses éléments caractéristiques, tels que définis dans les revendications qui suivent. A person skilled in the art will in fact be able to make modifications to the present invention, without going beyond the scope of its characteristic elements, as defined in the claims which follow.
Références bibliographiques. Bibliographic references.
1. Biochem. Biophys. Res. Commun, 48, 1972, p 76-84 1. Biochem. Biophys. Res. Commun, 48, 1972, p 76-84
2. Biochem. Biophys. Acta, 677, 1981 , p 313-3172. Biochem. Biophys. Acta, 677, 1981, p 313-317
3. Biochem. Journal, 225, 1985, p 745-752 3. Biochem. Journal, 225, 1985, p 745-752
4. Diabète et Métabolisme, 14, 1988, p 25-30 4. Diabetes and Metabolism, 14, 1988, p 25-30
5. J. Clin. Invest., 91,1993, p 2463-2469 5. J. Clin. Invest., 91.1993, p 2463-2469
6. Science, 232, 1986, p 1629- 1632 6. Science, 232, 1986, p 1629-1632
7. Biochim. Biophys. Acta, 77, p 1963, 676 7. Biochim. Biophys. Acta, 77, p 1963, 676
8. J. Invest. Dermatol., 99, 1992, p 306-309 8. J. Invest. Dermatol., 99, 1992, p 306-309
9. J. Invest. Dermatol., 91, 1988, p 472-477 9. J. Invest. Dermatol., 91, 1988, p 472-477
Annexe. Annex.
Annexe (suite). Annex (continued).
Annexe (suite et fin). Annex (continuation and end).
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU62277/96A AU6227796A (en) | 1996-03-19 | 1996-05-30 | Novel cosmetic or dermatological compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9603402A FR2746316B1 (en) | 1996-03-19 | 1996-03-19 | NEW COSMETOLOGICAL OR DERMATOLOGICAL COMPOSITIONS |
FR96/03402 | 1996-03-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996028008A2 true WO1996028008A2 (en) | 1996-09-19 |
WO1996028008A3 WO1996028008A3 (en) | 1997-03-13 |
Family
ID=9490311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1996/000811 WO1996028008A2 (en) | 1996-03-19 | 1996-05-30 | Novel cosmetic or dermatological compositions for controlling skin ageing |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6227796A (en) |
FR (1) | FR2746316B1 (en) |
WO (1) | WO1996028008A2 (en) |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033475A1 (en) * | 1997-02-03 | 1998-08-06 | Laboratoires Serobiologiques | Active synergetic complex and cosmetic and/or pharmaceutical product containing this complex |
WO1998034590A1 (en) * | 1997-02-11 | 1998-08-13 | Laboratoires Serobiologiques (Societe Anonyme) | Active composition for combating the effects of the cold and cosmetic product containing this composition |
WO1998042308A1 (en) * | 1997-03-25 | 1998-10-01 | Kao Corporation | Preventives for skin aging |
FR2765106A1 (en) * | 1997-06-27 | 1998-12-31 | Dior Christian Parfums | USE OF CROSSLINKED TANNINS IN THE PRESENCE OF NON-CROSSLINKED PROTEINS WITH TANNINS AS COSMETIC AGENTS TO IMPROVE SKIN SMOOTHING AND / OR TO OBTAIN AN ASTRINGENT EFFECT |
WO1999043352A1 (en) | 1998-02-24 | 1999-09-02 | Fujisawa Pharmaceutical Co., Ltd. | Preventives/remedies for skin aging |
FR2776188A1 (en) * | 1998-03-20 | 1999-09-24 | Fabre Pierre Dermo Cosmetique | Glycylglycine oleamide to combat the effects of skin aging |
US6048549A (en) * | 1997-12-19 | 2000-04-11 | Johnson & Johnson Consumer Companies, Inc. | Powder compositions |
WO2000050057A1 (en) | 1999-02-22 | 2000-08-31 | Bernstein Eric F | Compositions and methods for prevention of photoaging |
WO2000059462A1 (en) * | 1999-03-31 | 2000-10-12 | Pentapharm Ag | Composition for cosmetic and dermatological skin care |
EP1155677A2 (en) * | 2000-05-10 | 2001-11-21 | Fan Tech Ltd. | Methods and compositions for inhibiting free radical polymerization in skin and hair |
US6322778B1 (en) | 1998-02-10 | 2001-11-27 | Johnson & Johnson Consumer Companies, Inc. | Hair conditioning compositions comprising a quaternary ammonium compound |
EP1163900A1 (en) * | 1998-11-05 | 2001-12-19 | Protease Sciences, Incorporated | Cosmetic compositions containing human type serine protease inhibitors |
WO2002007697A1 (en) * | 2000-07-26 | 2002-01-31 | Cognis France | Synergistically active mixture which inhibits hair growth |
FR2815866A1 (en) * | 2000-10-31 | 2002-05-03 | Sephra | METHOD AND DERMATOLOGICAL AND / OR COSMETIC COMPOSITION ANTAGONIZING THE ADHESION EFFECT OF CIRCULATING CELLS |
FR2815872A1 (en) * | 2000-10-31 | 2002-05-03 | Sephra | Topical use of arginine pyrrolidone-2-carboxylate as dermal pacifier, antiirritant, and antiaging agent |
US6586628B2 (en) | 2000-05-10 | 2003-07-01 | The United States Of America, As Represented By The Secretary Of Agriculture | 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
US6638909B1 (en) | 1996-11-01 | 2003-10-28 | Ethicon, Inc. | Wound healing compositions containing alpha-1-antitrypsin |
FR2854069A1 (en) * | 2003-04-23 | 2004-10-29 | Silab Sa | A method of obtaining a soya active principle for use in anti-aging and anti-wrinkle compositions by solubilizing soya cake at acid pH and soya fiber at basic pH, hydrolyzing each with proteases, concentrating and combining |
EP1479370A1 (en) * | 2000-05-10 | 2004-11-24 | The United States of America | 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
EP1708677A2 (en) * | 2004-01-07 | 2006-10-11 | E-L Management Corp. | Cosmetic composition containing a protein and an enzyme inhibitor |
WO2006106805A1 (en) * | 2005-03-30 | 2006-10-12 | Kyowa Hakko Kogyo Co., Ltd. | Method of improving the storage stability of substance |
FR2897776A1 (en) * | 2006-02-28 | 2007-08-31 | Oreal | ANTI-AGE COSMETIC COMPOSITION |
EP1867713A1 (en) * | 2005-03-30 | 2007-12-19 | Kyowa Hakko Kogyo Co., Ltd. | Method of improving storage stability of dried microorganisms |
US8741359B2 (en) | 2001-05-03 | 2014-06-03 | Basf Beauty Care Solutions France S.A.S. | Method for testing a substance which is potentially active in the field of lipolysis and its mainly cosmetic use |
AU2012216795B2 (en) * | 1999-11-05 | 2015-07-09 | Johnson & Johnson Consumer Companies, Inc. | Soy depigmenting and skin care compositions |
US9310369B2 (en) | 1998-09-18 | 2016-04-12 | Alere Scarborough, Inc. | Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies |
US9989529B2 (en) | 1998-08-25 | 2018-06-05 | Alere Scarborough, Inc. | Method for detection of Legionella bacteria employing purified antigen-specific antibodies |
EP1139974B2 (en) † | 1999-11-05 | 2018-11-28 | Johnson & Johnson Consumer Companies, Inc. | Soy depigmenting and skin care compositions |
CN112451433A (en) * | 2019-09-06 | 2021-03-09 | 广东丸美生物技术股份有限公司 | Green soy bean extract and preparation method and application thereof |
WO2021145672A1 (en) * | 2020-01-15 | 2021-07-22 | 주식회사 휴메딕스 | Arginine aspartate-containing composition for suppressing old person smell |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7758878B2 (en) | 2003-10-10 | 2010-07-20 | Access Business Group International Llc | Cosmetic treatment system and methods |
JP2007508320A (en) * | 2003-10-10 | 2007-04-05 | アクセス ビジネス グループ インターナショナル エルエルシー | A composition comprising rosmarinusofficinalis plant extract, Centella, Echinacea or Alpinia plant extract, and DNA repair enzyme |
EP2275078B1 (en) * | 2004-08-13 | 2016-12-07 | Henkel AG & Co. KGaA | Cosmetic and dermatological compositions comprising (2-hydroxyethyl)urea |
DE102005012554A1 (en) * | 2005-03-16 | 2006-09-28 | Beiersdorf Ag | Cosmetic preparation with hyaluronic acid |
FR2906463B1 (en) * | 2006-09-28 | 2012-09-21 | Oreal | SUPERFICIAL PEELING COMPOSITION CONTAINING GLYCOSAMINAGLYCAN |
FR2943253B1 (en) * | 2009-03-20 | 2011-04-22 | Oreal | COMPOSITION CONTAINING THE ASSOCIATION OF MADECASSOSIDE, ARGININE AND POLYSORBATE |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56155298A (en) * | 1980-05-02 | 1981-12-01 | Tanabe Seiyaku Co | Shampoo composition |
JP2652556B2 (en) * | 1988-08-29 | 1997-09-10 | 株式会社浅井ゲルマニウム研究所 | Organic germanium compound and method for producing the same |
FR2666226B1 (en) * | 1990-08-30 | 1994-10-28 | Jean Noel Thorel | PROTECTIVE SKIN COMPOSITION. |
FR2675692A1 (en) * | 1991-04-24 | 1992-10-30 | Oreal | ANTI-OXIDANT SYSTEM CONTAINING PYRROLIDONE CARBOXYLATE LYSINE AND / OR ARGININE PYRROLIDONE CARBOXYLATE EITHER BEING ASSOCIATED WITH A PHENOLIC DERIVATIVE AND ITS USE IN COSMETICS. |
SG52390A1 (en) * | 1992-02-13 | 1998-09-28 | Torf Ets | Amadori reaction compounds and products process for their manufacture and their use |
FR2710839B1 (en) * | 1993-10-08 | 1995-12-08 | Rocher Yves Biolog Vegetale | Cosmetic composition and aesthetic treatment method opposing aging of the skin. |
FR2714599B1 (en) * | 1993-12-30 | 1996-02-09 | Oreal | Composition for fighting against aging, acting simultaneously on the superficial and deep layers of the skin, its use. |
-
1996
- 1996-03-19 FR FR9603402A patent/FR2746316B1/en not_active Expired - Lifetime
- 1996-05-30 WO PCT/FR1996/000811 patent/WO1996028008A2/en active Application Filing
- 1996-05-30 AU AU62277/96A patent/AU6227796A/en not_active Abandoned
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6638909B1 (en) | 1996-11-01 | 2003-10-28 | Ethicon, Inc. | Wound healing compositions containing alpha-1-antitrypsin |
FR2758984A1 (en) * | 1997-02-03 | 1998-08-07 | Serobiologiques Lab Sa | ACTIVE SYNERGISTIC COMPLEX AND COSMETIC AND / OR PHARMACEUTICAL PRODUCT COMPRISING THIS COMPLEX |
WO1998033475A1 (en) * | 1997-02-03 | 1998-08-06 | Laboratoires Serobiologiques | Active synergetic complex and cosmetic and/or pharmaceutical product containing this complex |
US6184199B1 (en) | 1997-02-03 | 2001-02-06 | Laboratoires Serobiologiques (Societe Anonyme) | Active synergetic complex and cosmetic and/or pharmaceutical product containing this complex |
FR2759295A1 (en) * | 1997-02-11 | 1998-08-14 | Serobiologiques Lab Sa | COMPOSITION ACTIVE AGAINST THE EFFECTS OF COLD AND COSMETIC PRODUCT COMPRISING SUCH A COMPOSITION |
WO1998034590A1 (en) * | 1997-02-11 | 1998-08-13 | Laboratoires Serobiologiques (Societe Anonyme) | Active composition for combating the effects of the cold and cosmetic product containing this composition |
US6224889B1 (en) | 1997-02-11 | 2001-05-01 | Laboratoires Serobiologiques (Societe Anonyme) | Active composition for combating the effects of the cold and cosmetic product containing this composition |
WO1998042308A1 (en) * | 1997-03-25 | 1998-10-01 | Kao Corporation | Preventives for skin aging |
FR2765106A1 (en) * | 1997-06-27 | 1998-12-31 | Dior Christian Parfums | USE OF CROSSLINKED TANNINS IN THE PRESENCE OF NON-CROSSLINKED PROTEINS WITH TANNINS AS COSMETIC AGENTS TO IMPROVE SKIN SMOOTHING AND / OR TO OBTAIN AN ASTRINGENT EFFECT |
WO1999000110A1 (en) * | 1997-06-27 | 1999-01-07 | Parfums Christian Dior | Use of tannins cross-linked in the presence of proteins non-cross-linked with the tannins |
US6660304B2 (en) | 1997-12-19 | 2003-12-09 | Johnson & Johnson Consumer Companies, Inc | Method of treating prickly heat |
US6048549A (en) * | 1997-12-19 | 2000-04-11 | Johnson & Johnson Consumer Companies, Inc. | Powder compositions |
US6426092B1 (en) * | 1997-12-19 | 2002-07-30 | Johnson & Johnson Consumer Companies, Inc. | Powder compositions comprising a skin irritation reducing agent |
US6322778B1 (en) | 1998-02-10 | 2001-11-27 | Johnson & Johnson Consumer Companies, Inc. | Hair conditioning compositions comprising a quaternary ammonium compound |
WO1999043352A1 (en) | 1998-02-24 | 1999-09-02 | Fujisawa Pharmaceutical Co., Ltd. | Preventives/remedies for skin aging |
EP1057491A4 (en) * | 1998-02-24 | 2006-04-12 | Astellas Pharma Inc | Preventives/remedies for skin aging |
EP1057491A1 (en) * | 1998-02-24 | 2000-12-06 | Fujisawa Pharmaceutical Co., Ltd. | Preventives/remedies for skin aging |
FR2776188A1 (en) * | 1998-03-20 | 1999-09-24 | Fabre Pierre Dermo Cosmetique | Glycylglycine oleamide to combat the effects of skin aging |
WO1999048470A1 (en) * | 1998-03-20 | 1999-09-30 | Pierre Fabre Dermo-Cosmetique | Glycylglycine oleamide in dermo-cosmetology |
US9989529B2 (en) | 1998-08-25 | 2018-06-05 | Alere Scarborough, Inc. | Method for detection of Legionella bacteria employing purified antigen-specific antibodies |
US9921220B2 (en) | 1998-09-18 | 2018-03-20 | Alere Scarborough, Inc. | Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies |
US9310369B2 (en) | 1998-09-18 | 2016-04-12 | Alere Scarborough, Inc. | Process and materials for the rapid detection of Streptococcus pneumoniae employing purified antigen-specific antibodies |
EP1163900A1 (en) * | 1998-11-05 | 2001-12-19 | Protease Sciences, Incorporated | Cosmetic compositions containing human type serine protease inhibitors |
EP1162934A1 (en) * | 1999-02-22 | 2001-12-19 | Eric F. Bernstein | Compositions and methods for prevention of photoaging |
WO2000050057A1 (en) | 1999-02-22 | 2000-08-31 | Bernstein Eric F | Compositions and methods for prevention of photoaging |
EP1162934A4 (en) * | 1999-02-22 | 2005-01-26 | Eric F Bernstein | COMPOSITIONS AND METHODS FOR PREVENTING LIGHT AGING |
WO2000059462A1 (en) * | 1999-03-31 | 2000-10-12 | Pentapharm Ag | Composition for cosmetic and dermatological skin care |
AU2012216795B2 (en) * | 1999-11-05 | 2015-07-09 | Johnson & Johnson Consumer Companies, Inc. | Soy depigmenting and skin care compositions |
EP1139974B2 (en) † | 1999-11-05 | 2018-11-28 | Johnson & Johnson Consumer Companies, Inc. | Soy depigmenting and skin care compositions |
US6545052B2 (en) | 2000-05-10 | 2003-04-08 | Fan Tech, Ltd. | Methods and compositions for inhibiting free radical polymerization in skin and hair |
US7169815B2 (en) | 2000-05-10 | 2007-01-30 | The United States Of America As Represented By The Secretary Of Agriculture | 3-methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
US6586628B2 (en) | 2000-05-10 | 2003-07-01 | The United States Of America, As Represented By The Secretary Of Agriculture | 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
EP1155677A2 (en) * | 2000-05-10 | 2001-11-21 | Fan Tech Ltd. | Methods and compositions for inhibiting free radical polymerization in skin and hair |
EP1155677A3 (en) * | 2000-05-10 | 2002-01-09 | Fan Tech Ltd. | Methods and compositions for inhibiting free radical polymerization in skin and hair |
EP1479370A1 (en) * | 2000-05-10 | 2004-11-24 | The United States of America | 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
US6653505B2 (en) | 2000-05-10 | 2003-11-25 | The United States Of America As Represented By The Secretary Of Agriculture | 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
WO2001085681A3 (en) * | 2000-05-10 | 2002-06-06 | Thomas P Abbott | 3-methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
US7053243B2 (en) | 2000-05-10 | 2006-05-30 | The Fanning Corporation | 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
WO2002007697A1 (en) * | 2000-07-26 | 2002-01-31 | Cognis France | Synergistically active mixture which inhibits hair growth |
FR2815866A1 (en) * | 2000-10-31 | 2002-05-03 | Sephra | METHOD AND DERMATOLOGICAL AND / OR COSMETIC COMPOSITION ANTAGONIZING THE ADHESION EFFECT OF CIRCULATING CELLS |
WO2002036094A3 (en) * | 2000-10-31 | 2002-08-08 | Sephra | Method and dermatological and/or cosmetic composition for inhibiting the adhesion effect of circulating cells |
FR2815872A1 (en) * | 2000-10-31 | 2002-05-03 | Sephra | Topical use of arginine pyrrolidone-2-carboxylate as dermal pacifier, antiirritant, and antiaging agent |
US8741359B2 (en) | 2001-05-03 | 2014-06-03 | Basf Beauty Care Solutions France S.A.S. | Method for testing a substance which is potentially active in the field of lipolysis and its mainly cosmetic use |
FR2854069A1 (en) * | 2003-04-23 | 2004-10-29 | Silab Sa | A method of obtaining a soya active principle for use in anti-aging and anti-wrinkle compositions by solubilizing soya cake at acid pH and soya fiber at basic pH, hydrolyzing each with proteases, concentrating and combining |
WO2004096168A1 (en) * | 2003-04-23 | 2004-11-11 | Societe Industrielle Limousine D'application Biologique, Dite Silab | Method for obtaining an active ingredient from soya having anti-aging properties, compositions and use of said compositions for cosmetic purposes |
EP1708677A2 (en) * | 2004-01-07 | 2006-10-11 | E-L Management Corp. | Cosmetic composition containing a protein and an enzyme inhibitor |
EP1708677A4 (en) * | 2004-01-07 | 2010-12-22 | E L Management Corp | Cosmetic composition containing a protein and an enzyme inhibitor |
EP1867713A4 (en) * | 2005-03-30 | 2010-04-28 | Kyowa Hakko Bio Co Ltd | METHOD FOR IMPROVING THE STORAGE STABILITY OF A DRIED MICROORGANISM |
WO2006106805A1 (en) * | 2005-03-30 | 2006-10-12 | Kyowa Hakko Kogyo Co., Ltd. | Method of improving the storage stability of substance |
EP1867713A1 (en) * | 2005-03-30 | 2007-12-19 | Kyowa Hakko Kogyo Co., Ltd. | Method of improving storage stability of dried microorganisms |
FR2897776A1 (en) * | 2006-02-28 | 2007-08-31 | Oreal | ANTI-AGE COSMETIC COMPOSITION |
CN112451433A (en) * | 2019-09-06 | 2021-03-09 | 广东丸美生物技术股份有限公司 | Green soy bean extract and preparation method and application thereof |
WO2021145672A1 (en) * | 2020-01-15 | 2021-07-22 | 주식회사 휴메딕스 | Arginine aspartate-containing composition for suppressing old person smell |
KR20210091982A (en) * | 2020-01-15 | 2021-07-23 | 주식회사 휴메딕스 | Composition for Inhibiting Aging Odor Comprising Arginine Aspartate |
KR102315140B1 (en) * | 2020-01-15 | 2021-10-20 | 주식회사 휴메딕스 | Composition for Inhibiting Aging Odor Comprising Arginine Aspartate |
CN114980856A (en) * | 2020-01-15 | 2022-08-30 | 株式会社 Humedix | Composition comprising arginine aspartate for suppressing the odor of elderly people |
JP2023510655A (en) * | 2020-01-15 | 2023-03-14 | ヒューメディックス カンパニー,リミテッド | Composition for suppressing aging odor containing arginine aspartate |
Also Published As
Publication number | Publication date |
---|---|
AU6227796A (en) | 1996-10-02 |
FR2746316B1 (en) | 1998-06-12 |
WO1996028008A3 (en) | 1997-03-13 |
FR2746316A1 (en) | 1997-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996028008A2 (en) | Novel cosmetic or dermatological compositions for controlling skin ageing | |
EP1112057B1 (en) | Cosmetic or dermopharmaceutical use of peptides for healing, hydrating and improving skin appearance during natural or induced ageing (heliodermia, pollution) | |
FR2796278A1 (en) | USE OF AT LEAST ONE HYDROXYSTILENE AS ANTI-GLYCATION AGENT | |
EP1110539A1 (en) | Use of 3,3',5,5'-tetrahehydroxystilbene as a glycation inhibitor | |
FR2956818A1 (en) | Cosmetic use of peptide hydrolyzate from flax (Linum kind), as active agent in composition to soothe the skin, to prevent the damage or restore the skin barrier function and for preventing or treating skin inflammations e.g. reddening | |
EP1278532B1 (en) | Plant extract of the olea europaea species as no-synthase inhibitor and uses | |
WO2011077017A2 (en) | Cosmetic and/or pharmaceutical composition comprising an extract of carob as active agent for activating aquaporin expression | |
EP0913147B1 (en) | System comprising a phosphonic acid derivative and a metabisulfit for stabilization of ascorbic acid | |
EP1837013A1 (en) | Composition comprising hydroxyapatite and a calcium salt for reinforcing the barrier function of the skin and/or semi-mucus membranes. | |
EP0946138B1 (en) | Use of a potentilla erecta extract in the cosmetic and pharmaceutical field | |
CA2407334A1 (en) | Lipochroman-6 as no-synthase inhibitor and uses | |
WO2007144518A2 (en) | Use of a mimosa seed extract in a cosmetic composition | |
FR3051369B1 (en) | BEET HINT EXTRACTS, COMPOSITIONS AND USES | |
WO1998027957A1 (en) | Use of an extract of cordia dichotoma | |
WO2014009874A2 (en) | Cosmetic use for a harungana madagascariensis extract | |
WO2022129750A1 (en) | Cosmetic uses of a hippophae rhamnoides cake hydrolysate | |
FR3051672A1 (en) | COSMETIC OR DERMOCASMETIC COMPOSITION COMPRISING AN EXTRACT OF SUREAU AND AN ORGANIC SILLICIUM DERIVATIVE | |
FR2807316A1 (en) | Cosmetic, dermatological or pharmaceutical formulation, especially useful for protection of hair, contains dimethicone copolyol panthenyl phosphate compounds | |
FR3010307A1 (en) | COSMETIC OR DERMATOLOGICAL USE OF AVICULARIN | |
FR2828400A1 (en) | Cosmetic composition useful for improving skin condition comprises insulin-like growth factor or its mimetic and a retinoid | |
FR2835427A1 (en) | COSMETOLOGICAL AND / OR DERMATOLOGICAL COMPOSITION BASED ON BARBATIMAO EXTRACT | |
FR2984733A1 (en) | ASSOCIATION OF A NUCLEOPHILIC AGENT AND A NITROGEN OR PHOSPHORUS AGENT OF PKA GREATER THAN 11 FOR GLYCATED SKIN | |
FR2828402A1 (en) | Cosmetic composition useful for improving skin condition comprises specific insulin-like growth factor or it's mimetic and an isoflavonoid | |
FR2828401A1 (en) | Cosmetic composition useful for improving skin condition comprises insulin-like growth of specific factor or it's mimetic and ascorbic acid | |
FR2873919A1 (en) | Cosmetic use of a modulating agent (comprising a potassium channel opener and potassium) of the potassium concentration in keratinocytes, to decrease and slow down the differentiation of keratinocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 96527344 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |